Compare BTGO & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTGO | SGP |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | 603 | 65 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 961.8M | 643.9M |
| IPO Year | N/A | N/A |
| Metric | BTGO | SGP |
|---|---|---|
| Price | $6.03 | $19.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $14.83 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.6M | 50.1K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.41 | N/A |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.42 | $19.46 |
| 52 Week High | $15.30 | $30.56 |
| Indicator | BTGO | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 29.82 |
| Support Level | N/A | N/A |
| Resistance Level | $12.40 | $26.29 |
| Average True Range (ATR) | 0.89 | 1.59 |
| MACD | -0.48 | -0.38 |
| Stochastic Oscillator | 8.32 | 2.61 |
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.